Activation of cannabinoid CB1 receptors suppresses the ROS-induced hypersensitivity of rat vagal lung C-fiber afferents

Yeh, Chia-Yu; Ruan, Ting; Lin, Yu‐Jung; Hsu, Tien-Huan

doi:10.1016/j.pupt.2016.06.002

Cited by 5 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, a study by Yeh et al (2016) found that perivagal treatment with JWH133 did not attenuate H 2 O 2 -induced vagal lung C-fiber hypersensitivity in rats, reflecting the pathophysiology of airway hyperresponsiveness in asthmatic patients (Kuo and Lai, 2008), suggesting that CB2R activation does not reduce the hypersensitivity in vagal lung C-fibers. Furthermore, Bozkurt et al (2016) reported that JWH133 did not modify serotonin-induced hyperreactivity in tracheas obtained from dinitrofluorobenzene (DNFB) group of nonatopic asthmatic mice.…”

Section: Asthmamentioning

confidence: 96%

Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist

et al. 2021

View full text Add to dashboard Cite

The endocannabinoid system has attracted attention as a pharmacological target for several pathological conditions. Cannabinoid (CB2)-selective agonists have been the focus of pharmacological studies because modulation of the CB2 receptor (CB2R) can be useful in the treatment of pain, inflammation, arthritis, addiction, and cancer among other possible therapeutic applications while circumventing CNS-related adverse effects. Increasing number of evidences from different independent preclinical studies have suggested new perspectives on the involvement of CB2R signaling in inflammation, infection and immunity, thus play important role in cancer, cardiovascular, renal, hepatic and metabolic diseases. JWH133 is a synthetic agonist with high CB2R selectivity and showed to exert CB2R mediated antioxidant, anti-inflammatory, anticancer, cardioprotective, hepatoprotective, gastroprotective, nephroprotective, and immunomodulatory activities. Cumulative evidences suggest that JWH133 protects against hepatic injury, renal injury, cardiotoxicity, fibrosis, rheumatoid arthritis, and cancer as well as against oxidative damage and inflammation, inhibits fibrosis and apoptosis, and acts as an immunosuppressant. This review provides a comprehensive overview of the polypharmacological properties and therapeutic potential of JWH133. This review also presents molecular mechanism and signaling pathways of JWH133 under various pathological conditions except neurological diseases. Based on the available data, this review proposes the possibilities of developing JWH133 as a promising therapeutic agent; however, further safety and toxicity studies in preclinical studies and clinical trials in humans are warranted.

show abstract

Section: Asthmamentioning

confidence: 96%